Quick Facts

• Main Therapeutic Domains: Symptom management for respiratory conditions associated with airflow obstruction and excessive or viscous mucus.
• Relief of Symptoms: Helps in managing shortness of breath, coughing, and wheezing related to chronic obstructive pulmonary disease (COPD) and bronchial asthma.
• Mucus Clearance: Assists in promoting the clearance of respiratory secretions, which may facilitate easier expectoration.

---

Lasal Expectorant is an available therapeutic option for patients requiring management of certain chronic and acute respiratory conditions. Its use is indicated for conditions characterized by bronchospasm—a narrowing of the airways—combined with the production of thick, sticky mucus. This medication may assist in improving airflow within the lungs.

Specific therapeutic domains include providing relief from symptoms associated with bronchial asthma, chronic bronchitis, and other obstructive airway disorders such as chronic obstructive pulmonary disease (COPD). The components work in combination to help manage difficult breathing and reduce the discomfort associated with a congested cough.

The medication offers support for promoting the loosening and thinning of mucus, which may facilitate the clearance of secretions from the respiratory tract. Consult with a clinician to understand the approved uses and how the drug may help manage your specific symptoms.

Regulatory References

1. NIH MedlinePlus guidance on similar therapeutic agents

Population Eligibility and Contraindications

Official regulatory documents establish strict rules regarding who can and cannot use Lasal Expectorant, a combination of Salbutamol and Guaifenesin. Use is generally approved for adults and adolescents 12 years of age and over. Use in children younger than 2 years of age is not established and not recommended.

Eligibility Status	Key Population Restrictions (Regulatory Basis)
Contraindicated (Must Not Use)	Patients with a history of hypersensitivity to any component; those concurrently receiving non-selective beta-blocking drugs; and patients with Thyrotoxicosis (severe hyperthyroidism).
Conditional Use (Caution Required)	Patients with uncontrolled diabetes mellitus, arrhythmias, hypertension, or coronary insufficiency. Caution is advised in cases of severe renal impairment or severe hepatic impairment.
Reproductive Status (Not Recommended)	Use in pregnancy is not recommended unless the expected maternal benefit outweighs fetal risk. Use in nursing mothers is not recommended as Salbutamol is probably secreted in breast milk.

The eligibility profile defines absolute prohibitions and populations requiring special consideration based strictly on the pharmacological and physiological effects documented in the labeling.

Interactions with other medicines and products

Contraindicated and Restricted Combinations

Co-administration with Non-selective Beta-blocking Drugs (such as Propranolol) is generally restricted in regulatory documents. These agents may block the bronchodilator action and lead to severe bronchospasm. The use of other short-acting sympathomimetic aerosol bronchodilators concurrently is also restricted by regulatory labeling.

Interactions Requiring Extreme Caution

Extreme caution is documented for co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), as these may potentiate the effects of Salbutamol on the vascular system. A mandatory time separation of 14 days is required after stopping MAOI therapy before this product can be used. Use with other Adrenergic Drugs is also cautioned against due to the risk of deleterious cardiovascular effects.

Metabolic and Electrolyte Risk

Concurrent use of agents such as Diuretics, Xanthine Derivatives, or Corticosteroids may potentiate the risk of potentially serious hypokalaemia (low potassium levels). Corticosteroids also have an officially documented interaction of potentially exaggerating Salbutamol-induced blood sugar level increases. Additionally, the regulatory label notes that the beta2-agonist component may decrease serum Digoxin levels. Hypoxia, a medical condition, is noted as potentiating the hypokalaemia risk in acute severe asthma.

beta2-Adrenoceptor Modulation and Airway Caliber

The bronchodilating action involves Salbutamol acting as a selective agonist on beta2-adrenoceptors (beta2 AR) found on bronchial smooth muscle. Activation of the beta2 AR triggers a molecular cascade that increases intracellular cAMP, which subsequently inhibits mechanisms responsible for muscle contraction, specifically by lowering free calcium ion (Ca^2+) concentrations. This results in the core physiological consequence of bronchial smooth muscle relaxation, which directly widens the airway lumen.

---

Neurogenic Secretion Pathway and Mucus Rheology

The expectorant mechanism of Guaifenesin operates indirectly by stimulating afferent nerve endings in the gastric mucosa, which activates a parasympathetic reflex arc to the lungs. This neurogenic pathway increases glandular output, leading to a rise in the volume and hydration of bronchial secretions. The key physiological effect is the reduction of mucus viscosity and adhesiveness, which facilitates mucociliary transport.

---

Mechanistic Synergy: Airway and Content Adjustment

The two mechanisms are synergistically applied that affect separate but concurrent physiological mechanisms: Salbutamol modifies the container (the airway diameter), while Guaifenesin modifies the content (the quality of the mucus). This results in a mechanism where the increased airway diameter is coupled with thinned, non-adherent mucus, which modifies the conditions necessary for respiratory secretion clearance.

Administration Protocol

Lasal Expectorant, an oral solution (syrup) containing Salbutamol and Guaifenesin, is administered by swallowing and not by any other route. The medicine is typically taken two to three times daily, though some regimens permit up to four administrations per day, reflecting the four- to six-hour duration of action of the bronchodilator component.

For proper use, the bottle must be shaken before measuring a dose. The prescribed volume must be accurately measured using a calibrated dosing device supplied with the product to ensure the correct milligram dose is delivered. The administration timing is flexible in relation to meals and may be taken with or without food.

Official Dosing Ranges by Population

The established usage guidelines provide specific volume ranges for different age groups. The dose or frequency of administration should not be increased without specific medical instruction.

Population Group	Standard Volume Dose (Based on 1 mg Salbutamol per 5 mL strength)	Frequency (Times Daily)
Adults and Children over 12 years	10 mL to 20 mL	2 to 3
Children 6 to 12 years	10 mL	2 to 3
Children 2 to 6 years	5 mL to 10 mL	2 to 3
Older Adults	Initiate with 5 mL to 10 mL	3 to 4

Missed Dose Instructions

If a dose is missed, the individual should skip the missed dose and continue with the next scheduled dose at the usual time; do not double doses to compensate for the forgotten administration. Adherence to the scheduled intervals is key to maintaining the correct use profile of the medication.

Research Evidence / Overview of Studies for Lasal Expectorant

Evidence for Use in Productive Cough and Acute Symptoms

Research examined the dual combination of Salbutamol and Guaifenesin in contexts involving cough where symptoms are acute and accompanied by excessive mucus. The evidence base is drawn from short-term Randomized Controlled Trials (RCTs) and studies that included comparator arms. These trials were used in research exploring how symptoms change over time and applied in studies examining patient-reported experiences related to physical discomfort from coughing.

Studies monitored outcomes related to patient-reported frequency and severity of the cough. Research also examined changes in the physical characteristics of respiratory secretions. Findings describe patterns observed in the studies related to outcomes linked to irritative states during acute respiratory episodes.

Evidence for Use in Chronic Respiratory Conditions

Lasal Expectorant was evaluated in contexts related to symptomatic management in chronic conditions such as Bronchial Asthma, Chronic Bronchitis, and Emphysema, which are conditions characterized by fluctuating or episodic manifestations. The evidence for this use is often derived from regulatory reviews and assessments that bridge the established pharmacological action of the individual active ingredients.

The research examined outcomes related to systemic or functional imbalance, such as measures related to respiratory obstruction and changes in functional lung parameters, particularly from the bronchodilator component. Studies monitored responses over defined time intervals, relevant in trials assessing short-term or episodic symptom patterns.

Key Limitations and Research Gaps

Overall, certainty remains low in certain areas of the research base for Lasal Expectorant. A major limitation is the reliance on evidence generated for the individual active components rather than extensive, dedicated trials for the specific fixed-dose combination syrup. Follow-up durations were limited in the trials. Consequently, while research provides context, research does not determine whether an individual will respond similarly, as the results reflect the specific conditions under which they were conducted.

Common questions about Lasal Expectorant (FAQ)

Q: Is Lasal Expectorant safe for people with high blood pressure?

Official regulatory documents advise that this medicine should be administered with caution to patients with pre-existing conditions such as hypertension (high blood pressure). This precaution is related to the bronchodilator component of the formulation. Patients with this pre-existing condition may need to discuss its use with a healthcare provider.

Q: Are there different strengths or formulations of Lasal Expectorant?

Official product information shows that Lasal Expectorant is primarily supplied as a syrup or oral solution. However, the active ingredients are also described as being available in a capsule formulation, though the specific availability of this combination product may vary by region.

Q: What kind of cough is Lasal Expectorant intended for?

Regulatory indications state that this medicine is used for managing a productive cough—meaning a cough that brings up mucus. Its purpose is to help loosen and thin the excessive, thick mucus associated with conditions like bronchospasm, thereby aiming to make the cough more efficient.

Q: Are there any long-term effects associated with using Lasal Expectorant?

Long-term use of this medicine is generally associated with formulations containing sugar. Official regulatory warnings state that prolonged use of sugar-containing syrups may increase the risk of dental caries (cavities), and official guidance is available regarding the maintenance of adequate dental hygiene during use.

Q: What is the difference between Lasal Expectorant and another common expectorant?

Lasal Expectorant is classified as a combination product, meaning it contains two active ingredients that perform two distinct functions. It contains an expectorant to thin mucus and a bronchodilator to widen the airways. Most common expectorants contain only the single ingredient to address mucus.

Q: Is Lasal Expectorant suitable for people who have asthma?

The medicine is indicated for respiratory disorders, including bronchial asthma, when complicated by both airway tightening (bronchospasm) and excessive mucus. Official guidance notes that the product is intended for symptomatic management but is generally not described as a primary, single-agent treatment for persistent asthma.

Q: Does Lasal Expectorant help with congestion or just the cough?

The expectorant component (Guaifenesin) is officially used for the relief of chest congestion (often called a 'wet' chest cough) by thinning the secretions in the bronchial tubes. This helps to facilitate the clearance of mucus from the lungs.

Q: What is the typical time frame that Lasal Expectorant is used for?

Regulatory labeling contains a general warning regarding cough persistence beyond a defined timeframe (e.g., one week). This guidance establishes the product as an acute or short-term treatment related to acute symptoms.

Q: Can Lasal Expectorant be crushed or mixed with food/liquid?

As an oral solution (syrup), crushing is not applicable. Regulatory documents caution that mixing the syrup with certain common liquid preparations may lead to precipitation (where the ingredients separate). However, dilution with purified water is sometimes permissible, but the resulting mixture must be used within a specified, short time period.

Q: Is Lasal Expectorant an antibiotic?

No. The medicine is classified as a combination Expectorant and a Selective Beta-2-Adrenoceptor Agonist (a type of bronchodilator). It is not in the class of antibiotics.

Q: Does Lasal Expectorant contain pseudoephedrine?

The active ingredients listed in the formulation are Salbutamol and Guaifenesin. Official product information confirms that pseudoephedrine is not listed as an active component in this specific combination product.

Q: Can Lasal Expectorant be taken for a dry cough?

As an expectorant, this type of medicine is designed to help loosen and thin mucus. Official regulatory standards generally exclude this product from indications specifically targeting the relief of a dry cough.

Q: How long does it take for Lasal Expectorant to start working?

Studies examining the pharmacokinetics of one of the active ingredients, Guaifenesin, indicate that it reaches its highest concentration in the blood within approximately 15 minutes after oral administration. Individual response times, however, may vary.

Q: Is it normal to feel a bit dizzy after using Lasal Expectorant?

Regulatory documents list dizziness as a potential side effect. This effect is generally associated with the expectorant component (Guaifenesin).

Q: Does Lasal Expectorant make you feel drowsy or sleepy?

Official product information lists drowsiness as a potential side effect. This effect is generally associated with the Guaifenesin component of the medicine.

Q: Can Lasal Expectorant cause stomach upset?

Official adverse reaction profiles for this medicine include the potential for gastrointestinal discomfort and associated symptoms such as nausea and vomiting. These effects are typically associated with the Guaifenesin component.

Q: Is Lasal Expectorant a controlled substance?

The active ingredient Guaifenesin is generally not listed as a controlled substance according to federal regulatory schedules (CSA Schedule N/A). Its classification is as an expectorant.

Q: Can Lasal Expectorant affect my ability to drive or operate machinery?

Because potential side effects include dizziness and drowsiness, official safety information notes these risks. Due to this potential, caution is generally advised when engaging in tasks like driving or operating heavy machinery.

Q: Is there a risk of dependence or addiction with Lasal Expectorant?

The regulatory warning profile for the active ingredient Guaifenesin specifically lists 'None' for effects related to drug abuse or dependence.

Q: Does taking Lasal Expectorant at night affect sleep?

The side effects profile for the Salbutamol component includes effects such as nervous tension, insomnia (difficulty sleeping), and restlessness. These potential effects may impact sleep.

Q: Can Lasal Expectorant interact with herbal supplements?

Official information regarding general drug usage often advises caution with combination use. Consultation with a healthcare provider regarding all supplements is often recommended due to the potential for interactions that may lead to unintended effects.

Q: What happens if I accidentally take more Lasal Expectorant than recommended?

Overdose symptoms include transient beta agonist effects (from Salbutamol) and potential hypokalaemia (low potassium). Very large doses of Guaifenesin may cause nausea and vomiting. Overdose on this product requires urgent medical attention due to the potential for serious effects.

Q: Is Lasal Expectorant available over the counter or does it require a prescription?

While the single ingredient Guaifenesin is commonly available over-the-counter (OTC), the specific combination product containing Salbutamol and Guaifenesin is listed as a prescription-only drug (Rx) in some regulatory regions.

Q: What color are the tablets/liquid of Lasal Expectorant?

Official product descriptions note that the syrup formulations are typically packaged in amber bottles. Some capsule formulations containing the same active ingredients are described as having a fine, white powder inside a gray and blue capsule shell.

Q: Are generic versions of Lasal Expectorant available?

The active ingredients, Salbutamol and Guaifenesin, are widely available in generic forms and are marketed under various brand names. Generic availability for the specific combination product may vary by region.

Q: Is it possible to take Lasal Expectorant for too long?

Official regulatory labeling contains a general warning that if a cough continues for more than one week, the product is intended for short-term treatment related to acute symptoms.

Q: What is the active ingredient's official safety classification?

In some regulatory documents, both active ingredients, Salbutamol and Guaifenesin, are classified as Pregnancy Category C. This classification indicates that the potential for benefit may outweigh potential risks, but official eligibility profiles state that use during pregnancy is not recommended unless the expected maternal benefit outweighs potential fetal risk.

The official storage and disposal requirements for Lasal Expectorant syrup are mandated to preserve the product's integrity and ensure public safety.

Storage Conditions and Handling

The product must be stored at temperatures not exceeding 30 C and should be protected from light and moisture. The official labeling directs users to not freeze the syrup. To maintain stability, the medication must be kept in its original container and the container must be kept tightly closed.

Child Safety and Disposal

All medication must be kept out of reach of children.

Disposal of unused or expired syrup should follow local requirements, with the preferred method being the use of an official drug take-back program. If a take-back option is unavailable, the product may be disposed of in household trash by mixing it with an undesirable substance (such as used coffee grounds or kitty litter) and securing it in a sealed container; do not flush it down the toilet or drain.